This website is intended for healthcare professionals only.
INSIGHTS INTO RECENT ADVANCES IN 3L TREATMENT OF mCRC
Prof. Julien Taieb
MD, PhD, Head Of The Gastroenterology and Gastrointestinal Oncology
Department, Georges Pompidou - European hospital, Paris
Prof. Nieves Martinez Lago
MD, PhD
Consultant medical Oncologist ​university hospital complex of santiago de compostela, Santiago de Compostela, Spain.
This webinar focuses on recent advances in 3L treatment of metastatic colorectal cancer (mCRC). The speakers discuss the newest treatment options recommended by ESMO, including FTD/TPI combined with bevacizumab as well as targeted treatments for KRAS-G12C mutated mCRC.
Key points covered
This webinar covers the following points:
mCRC prognosis, with more patients becoming eligible for treatment in 3L and beyond
Recent ESMO recommendations in 3L mCRC
FTD/TPI + bevacizumab as the new standard treatment for 3L mCRC: results from the SUNLIGHT clinical trial and BeTAS real-world study
Sotorasib + cetuximab as a new 3L targeted treatment option for KRAS G12C-mutated mCRC: results from the Codebreak 300 trial
Beyond 3L: recent approval of fruquintinib post-FTD/TPI or regorafenib, with results from the Fresco-2 trial
Webinar highlights
Full Webinar Replay
Featured Speakers
Profesor Julien Taieb
Julien Taieb received his MD and PhD qualifications in gastroenterology and immunology from the UniversitĂ© Pierre et Marie Curie (Paris VI), Paris, France, after completing a Bachelor of Science degree. He currently holds the position of Head of the Gastroenterology and Gastrointestinal Oncology Department at the Georges Pompidou European Hospital, UniversitĂ© de Paris, France. He is a regular reviewer for Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, British journal of cancer and the European Journal of Cancer. Professor Taieb is a member of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology, and a number of French gastrointestinal cooperative groups and societies, including the PRODIGE intergroup, the FĂ©dĂ©ration Francophone de CancĂ©rologie Digestive (FFCD), the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) and the SociĂ©tĂ© Nationale Française de Gastro-EntĂ©rologie (SNFGE). He is the founder of the AGEO French research group on GI tumors. He has a position in the administrative council or on the scientific committee of ESMO, FFCD and SNFGE. He is a member of ESMO nomination Committee since 2018. His main research topics are non-metastatic and metastatic colon cancer and pancreatic cancer.Â
Profesor Nieves Martinez Lago
Professor MartĂnez Lago is a consultant medical oncologist at the University Hospital Complex of Santiago de Compostela in Spain, specializing in gastrointestinal cancers, neuroendocrine tumors, and sarcomas.
She earned her degree in Medicine and Surgery from the University of Santiago de Compostela in 2008 and completed her residency in Medical Oncology at University Hospital Complex of Santiago de Compostela in 2014. Additionally, in 2013, she completed an internship as a clinical observer in the GI unit at the Royal Marsden Hospital in London.
In 2017, Professor MartĂnez Lago obtained her PhD from the University of Santiago de Compostela with the distinction Cum Laude.
Since July 2015, she has focused on the treatment of gastrointestinal cancers and neuroendocrine tumors, both in clinical practice and research.
She has co-authored over 30 publications and has presented more than 100 communications at national and international congresses.
